Covid19 Clinical Trial - Comparison of Cardiopulmonary Fitness Level With

Status Recruiting

Clinical Trial Summary

COVID-19 (Coronavirus disease 2019) is a new infectious disease caused by a virus named as SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2). Although it can have a devastating effect on many organs, the respiratory tract is particularly affected. In the course of the disease, a wide clinical spectrum is observed, from flu-like illness to lung failure. Some of the patients who survived the disease continue to have problems such as shortness of breath, fatigue, decrease in walking distance, decrease in participation in daily life activities. These problems suggest that the effects on respiratory and cardiac functions continue even after the disease ends. This study was designed to demonstrate the effects and extent of COVID-19 on cardiopulmonary capacity.

Clinical Trial Description

Aims of the research are that demonstrate change in cardiopulmonary fitness level in patients with COVID-19 according to normal values and reveal the relationship of this change with age, gender, physical activity level, disease severity and accompanying medical conditions. Patients older than 18 years old who are diagnosed with COVID-19 according to clinical symptoms and rt-PCR test positivity and at least 30 days past the end of their symptoms are accepted for the study. According to World Health Organization's (WHO) classification, COVID-19 disease severity is determined. Physical activity level of the patients before COVID-19 is evaluated with International Physical Activity Questionnaire. Risk of anxiety and depression of the patients is identified with Hospital Anxiety and Depression Scale (HADS), which has 14 questions. To evaluate cardiopulmonary fitness level, cardiopulmonary exercise test (CPET) and 6-minute walk test are applied. Cardiopulmonary exercise test is gold standard to determine cardiac and respiratory functions. Pulmonary function test is performed to identify the conditions that affect the results of cardiopulmonary exercise test. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04753346
Study type	Observational
Source	Ankara University
Contact	Burak K Turan
Phone	90(312)5082822
Email	burakkamilturan@gmail.com
Status	Recruiting
Phase
Start date	February 15, 2021
Completion date	January 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04333732` - CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION	Phase 3
Completed	`NCT04357457` - Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia	Phase 3
Terminated	`NCT04435795` - Inhaled Ciclesonide for Outpatients With COVID19	Phase 2/Phase 3
Completed	`NCT04357444` - Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19	Phase 2
Completed	`NCT04357834` - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting	`NCT05052320` - Audiological Assessment of Recovered Covid 19 Subjects.
Withdrawn	`NCT04426344` - Core Warming of COVID-19 Patients	N/A
Recruiting	`NCT05595031` - Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
Terminated	`NCT04371978` - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19	Phase 3
Terminated	`NCT04401410` - Anti-SARS Cov-2 T Cell Infusions for COVID 19	Phase 1
Completed	`NCT04445337` - Stellate Ganglion Blockade in COVID-19 Positive Patients	N/A
Active, not recruiting	`NCT04374487` - Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications	Phase 2
Completed	`NCT04403243` - COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19	Phase 2
Completed	`NCT04375644` - Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
Completed	`NCT04394078` - Impact of COVID-19 Pandemic on Depression and Quality of Life
Recruiting	`NCT04407923` - Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
Completed	`NCT04426305` - Community Health Workers Against COVID19	N/A
Withdrawn	`NCT04519411` - Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure	N/A
Recruiting	`NCT04492514` - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation	Phase 2
Completed	`NCT04399980` - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison of Cardiopulmonary Fitness Level With Normal Values After COVID-19

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms